Sulfasala.zune is used commonly to treat and prevent relapses of chronic ulcerative colitis and to treat acute exacerbations of Crohn's disease (1). Total bilirubin (TBi1), conjugated bilirubin (Bc), and uncozijugated bilirubin (Bu) often are measured in patients with inflammatory bowel disease, to monitor the potential development of hepatobiliary complications of the disease, including sclerosing cholangitis, pericholangitis, cholecystitis, and chronic active hepatitis (1). We recently learned of a patient who was taking sulfasalazine for inflammatory bowel disease, whose Be concentration as measured by the Ektachem 400 was 9 mgfL, whereas his TBi1 was only 3 mg/L. The TBi1 was confirmed by analysis with a different type of the instrument. The product labeling that accompanies the Ektachem BuBc slide mentions sulfasalazine as a potential Departments of' Pathology and2 Pediatrics, University of Virginia Health SciencesCenter, Charlottesville, VA 22908.
Sulfasala.zune is used commonly to treat and prevent relapses of chronic ulcerative colitis and to treat acute exacerbations of Crohn's disease (1). Total bilirubin (TBi1), conjugated bilirubin (Bc), and uncozijugated bilirubin (Bu) often are measured in patients with inflammatory bowel disease, to monitor the potential development of hepatobiliary complications of the disease, including sclerosing cholangitis, pericholangitis, cholecystitis, and chronic active hepatitis (1). We recently learned of a patient who was taking sulfasalazine for inflammatory bowel disease, whose Be concentration as measured by the Ektachem 400 was 9 mgfL, whereas his TBi1 was only 3 mg/L. The TBi1 was confirmed by analysis with a different type of the instrument. The product labeling that accompanies the Ektachem BuBc slide mentions sulfasalazine as a potential interferent with absorbance measurements, but no characterization of this interference has been published. Here we characterize the positive interference of sulfasalazine in determination ofBc with the BuBc slide in the Ektachem 400 and 700 analyzers. We show a direct correlation between the concentration of sulfasalazine added to serum and the reported Bc, and we demonstrate that none of the major metabolites of the drug in blood contribute to this interference. Finally, the ultraviolet-visible spectra of sulfasalazine and its metabolites confirm and explain these findings.
MaterIals and Methods
We obtained serum samples from the patient described above and from three additional patients who were being treated with sulfasalazine for inflammatory bowel disease.
A 100 mg/L stock solution of sulfasalazine was prepared by dissolving sulfasalazine powder (Sigma Chemical Co., St. Louis, MO) in pooled human serum that contained no Bc detectable with the Ektachem 400 and 700. Aliquots of pooled human serum were supplemented with the stock sulfasalazine solution to yield final concentrations of 0, 5, 10, 25,50, 75, and 100 mg/L. Similarly, 100 mg/L solutions of the sulfasalazine metabolites were prepared by dissolving sulfapyridine powder (Sigma Chemical Co.), N4-acetylsulfapyridine powder (a gift from Pharmacia, Uppsala, Sweden), and 5'-OH-sulfapyridine powder (a gift from Pharmacia) in pooled human serum that contained no detectable Bc.
Bc, Bu, and TBi1 were determined with the Ektachem 400 and 700 analyzers, calibrated according to the manufacturefs specifications. The Ektachem calculates Bc and Bu by measuring the reflectances of the BuBc slide at 400 nm and 460 nm (2, 3) . TBi1 is determined by measuring the reflectance of the TBiI slide at 540 rim (3) (4) (5) .
For determination of ultraviolet-visible spectra, we prepared separate 100 mg/L solutions of sulfasalazine and its metabolites in 0.5 inmo]/L NaOH. Aliquots of each of these solutions were diluted with distilled water to yield concentrations of 10 mg/L. Ultraviolet-visible spectra were obtained with a Model DU-7 spectrophotometer (Beckman Instruments, Irvine, CA).
Results
Analysis of serum from each of the four patients taking sulfasalazine revealed a value for Bc greater than that for TBil as measured by the Ektachem 400 (Table 1) . In each case, the Bu was reported as less than -3 mgIL. We prospectively followed the case of patient four, a sevenyear-old girl begun on sulfasalazine for colitis. Before therapy with sulfasalazine, her TBi1 value was 1 mgfL, her Bc was 0, and her Bu was 0.5 mgfL as measured in the Ektachem. Two days after starting sulfasalazine, however, her TBi1 remained at 1 mg/L, her measured Bc increased to 12 mg/L, and her Bu was less than -3 mgIL (Ektachem 400).
Sulfasalazine added to pooled human serum at therapeutic concentrations (5-100 mgIL) (6, 7) increased the Bc concentration, as measured in the Ektachem 400 or 700, in a linear and dose-related fashion: Bc (mgIL) = 0.95[sulfasalazine (mgfL)] -2.7 (n = 7, r = 0.9992). In other words, each 1 mg/L of sulfasalazine increased the apparent Bc by 0.95 mg/L. Measured Bu was simultaneously decreased to values less than -3 mgfL, and TBi1 was unaffected. The same interference occurred in the Ektachem 700, but an algorithm prevented the instrument from reporting the Bc results. The Bu, however, was reported as less than -3 mgIL. Sulfapyridine, N4-acetylsulfapyridine, and 5'-OH-sulfapyridine did not interfere with Bc or Bu analysis, even at concentrations up to 100 mg/L ( Table 2) .
The ultraviolet-visible spectrum of sulfasalazine consisted ofabsorption peaks at 238 am and 358 rim and a local absorption minimum at 285 nm, in agreement with data reported by McDonnell (8). Sulfasalazine showed strong absorbanee at 400 am (a = 8937 L/mol -cm), less absorbance at 460 am (a -2071 L/mol cm), and negligible absorbance at 540 rim (a = 77 L/mol cm). The metabolites showed negligible absorbance at or above 400 rim (molar absorptivities, <110 L/mol -cm).
Although it did not affect Bc or Bu analysis, the standard 100 mg/L serum solution of 5'-OH-sulfapyridine increased the measured TBi1 to 98 mg/L from a serum blank value of 5 mgfL (Table 2 ). An ultraviolet-visible absorption spectrum of this solution, with the serum blank as a reference, showed minimal absorbance at 540 am (a = 141 L/mol -cm), the primary wavelength used by the Ektachem to determine TBil.
DiscussIon
This study demonstrates a direct linear relationship between the concentration of sulfasalazine in serum and the apparent Bc measured in the Ektachem. The much greater absorbance of sulfasalazine at 400 rim compared with 460 am explains this positivebias.When bound to the mordant within the Ektachem BuBc slide,Bu and Bc have similar molar absorptivitiesat 400 am, whereas Bu has a greater molar absorptivity than Bc at 460 am (2). The Ektachem measures reflection densities at these two wavelengths and then solves simultaneous equations to calculate Bc and Bu. Inspection of these equations reveals that increased absorbance at 400 am would produce an increased Bc result and a decreased Bu (see Appendix). TBil is primarily measured at 540 am, and sulfasalazine's minimal absorbance at this wavelength did not cause measurable interference.
The major metabolites of sulfasalazine in blood showed no interference with the Ektachem's analysis of Bc or Bu. About 10% of orally ingested sulfasalazine appears in serum intact, and its median concentration in serum is only 12 mg/L (6, 7). Colomc bacteria convert most of the drug into sulfapyridine and 5-aininosalicylic acid. Sulfapyridine is subsequently absorbed and hepatically metabolized to N4-acetylsuufapyridine and 5'-OH-sulfapyridine, which are then glucuronidated and rapidly excreted via the kidneys. The median concentration of sulfapyridine and its metabolites in serum is about 50 mg/L (6, 7), and that of 5'-OH-sulfapyridine alone has been reported as <1 mgfL (9). Although thought to be the active moiety, owing to local effects on prostaglandin metabolism in the intestine (1), very little 5-aminosalicylic acid is absorbed, and its
